Supply with High Purity and Stable Quality
Chemical Name: Glimepiride
Synonyms: Amaryl
CAS: 93479-97-1
Glimepiride in the treatment of Noninsulin-Dependent Type 2 Diabetes Mellitus
API High Quality, Commercial Production
| Chemical Name | Glimepiride |
| Synonyms | Amaryl |
| CAS Number | 93479-97-1 |
| CAT Number | RF-API24 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C24H34N4O5S |
| Molecular Weight | 490.62 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White or Almost White Powder |
| Identification | IR (Similar to Standard) |
| Related Substances | |
| Cis-Isomer (A) | ≤0.80% |
| Sulfonamide (B) | ≤0.40% |
| Urethane (C) | ≤0.10% |
| 3-Isomer (D) | ≤0.20% |
| Any Other Impurity | ≤0.10% |
| Total Impurities | ≤0.50% |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.10% |
| Heavy Metals | ≤0.001% |
| Assay | 98.0%~102.0% |
| Test Standard | European Pharmacopeia (EP); United States Pharmacopoeia (USP) |
| Usage | Active Pharmaceutical Ingredient (API) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Glimepiride (CAS: 93479-97-1) with high quality, active pharmaceutical ingredient (API). Glimepiride is an antidiabetic drug that helps control blood sugar levels. Glimepiride is a long-acting, third-generation sulfonylurea with hypoglycemic activity.
Glimepiride (original trade name Amaryl) is an orally available medium-to-long-acting sulfonylurea antidiabetic drug. Like all sulfonylureas, glimepiride acts as an insulin secretagogue. It lowers blood sugar by stimulating the release of insulin from functioning pancreatic beta cells and by increasing sensitivity of peripheral tissues to insulin. Glimepiride likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin. Glimepiride is mainly used to treat patients with type 2 diabetes and can also decrease the chances that someone will develop complications of type 2 diabetes, such as kidney damage, blindness, nerve problems, loss of limbs, sexual function problems and heart attack or stroke. The drug was approved by the FDA in 1995 and is manufactured by Sanofi-Aventis. It can be used along with proper diet and exercise program and may also be used alone or with other antidiabetic medicines if need. The drug is available only with your doctor's prescription.
Glimepiride, the first of a new generation of sulfonylurea drugs, was introduced in Sweden in 1995 as a first-line therapy to lower blood glucose in patients with type II diabetes. Sulfonylureas exert their hypoglycemic function primarily by direct stimulation of insulin secretion in glucose-insensitive pancreatic β-cells and GLUT translocation in insulin-resistant fat and muscle cells. Once-daily, orally administered glimepiride in diabetes patients showed a more rapid and longer lasting glucose-lowering effect than the commonly used agent glibenclamide. Glimepiride can be used either as a monotherapy or in combination with insulin.